Biomea Fusion, Inc. (BMEA)
NASDAQ (NGS) NASDAQ (NGS) Primary Summary
After Golden Cross, Biomea Fusion, Inc. (BMEA)'s Technical Outlook is Bright
Biomea Fusion, Inc. (BMEA) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, BMEA's 50-day simple moving average crossed above its 200-day simple moving average, known as a "golden cross.
Citi sees up to 410% upside in 2 biotech stocks: is the risk worth it?
Citi analyst Yigal Nochomovitz sees enormous upside in two biotech stocks, but those forecasts reveal as much about risk as potential reward. Nochomovitz has a $7 target on Biomea Fusion, implying about 410% upside from the price used in Citi's call, while his $57 Syndax Pharmaceuticals target points to roughly 190%.
Biomea Fusion, Inc. (BMEA) Discusses Developments in Diabetes With Emphasis on Icovamenib and Clinical Trial Insights Transcript
Biomea Fusion, Inc. (BMEA) Discusses Developments in Diabetes With Emphasis on Icovamenib and Clinical Trial Insights Transcript
Biomea Fusion, Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Point72 Asset Management LP Point72 Asset Management LP | 32,792 | $45,580.88 | $43,285.44 | -$2,295.44 | -5.04% |
 George Song Superstring Capital Management LP | 250,000 | $450,000 | $425,000 | -$25,000 | -5.56% |
 Drew Phillips Fortitude Family Office LLC | 454 | $793.93 | $771.8 | -$22.13 | -2.79% |
 Hui Fai Tam Caitong International Asset Management Co. Ltd. | 68 | $94.94 | $115.6 | $20.66 | 21.76% |
 Jae Cho Marex Group plc | 100,000 | $313,600 | $132,000 | -$181,600 | -57.91% |
Biomea Fusion, Inc. (BMEA) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Biomea Fusion, Inc. ever had a stock split?
Biomea Fusion, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Michael J. Hitchcock CEO | NASDAQ (NGS) Exchange | 09077A106 CUSIP |
| US Country | 37 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Biomea Fusion, Inc. is a forward-thinking clinical-stage biopharmaceutical firm with a dedicated mission to pioneer the development of covalent small molecule drugs. With an emphasis on addressing genetically defined cancers and metabolic diseases, the company leverages cutting-edge science and research to break new ground in the medical field. Founded in 2017 and located in Redwood City, California, Biomea Fusion, Inc. represents a vibrant and innovative presence in the biopharmaceutical landscape, aiming to transform the treatment paradigms for patients suffering from serious health conditions.
Products and Services
BMF-219: Positioned as the flagship product in Biomea Fusion’s pipeline, BMF-219 marks a significant advancement in the treatment of both oncological and metabolic conditions. This covalent inhibitor of menin is specifically engineered for the management of liquid and solid tumors, providing a new hope for cancer patients. Beyond its application in oncology, BMF-219 is under investigation for its potential in addressing type 2 diabetes, showcasing the versatility and innovative approach of Biomea Fusion in leveraging its technology platform to meet diverse healthcare needs.
